Vlasova Hill
Minicircle DNA vaccines have emerged as a promising platform for the rapid and efficient production of immunogenic antigens, particularly in response to emerging infectious diseases such as SARS-CoV-2. Unlike conventional plasmid DNA vaccines, minicircle DNA vaccines lack bacterial sequences, thereby enhancing transgene expression, improving immunogenicity, and reducing potential inflammatory responses. The optimization of minicircle DNA vaccine production expressing the Receptor-Binding Domain (RBD) of SARSCoV- 2 is crucial for developing effective and scalable immunization strategies against COVID-19. The production of minicircle DNA vaccines involves a two-stage process that includes the initial propagation of parental plasmids in bacterial cultures followed by an in vivo recombination step to remove bacterial backbone sequences. This process results in a purified minicircle DNA construct that contains only the gene of interest and necessary regulatory elements, enhancing the efficiency of gene expression in host cells.
PDFShare this article
Journal of Genetics and DNA Research received 3 citations as per Google Scholar report
